Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-15

Clinical Trial Update: Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of oral OPS-2071 in Crohn's disease with active inflammation; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OPS-2071

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-06-15